Breaking News, Collaborations & Alliances

Merck, Zymeworks Extend Bi-specific Antibody Alliance

Merck gains expanded access to Azymetric platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Zymeworks has extended its research collaboration with Merck, dating back to August 2011. Additionally, Merck gains expanded access to Zymeworks’ Azymetric platform for the development of novel bi-specific antibody therapeutic candidates.   Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies generated through use of the Azymetric platform for certain therapeutic targets. Both companies will progress bi-specific therapeutic an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters